Huatai Securities Injects $15M Into Chinese Genetic, Protein Engineering Tech Start-Up

News Source: China Money Network.

Abiochem Biotechnology Co Ltd, a Chinese biotech start-up specialized in genetic and protein engineering technologies, has raised over RMB100 million (US$14.89 million) in a new round of financing led by Huatai Zijin Investment, a wholly-owned investment subsidiary of Chinese securities group Huatai Securities, according to a statement released on Wednesday.

This news article comes via China Money Network, who is the copyright owner of this information and news. has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of

You May Also Like